HHLA2 and pancreatic neoplasm: In 77.17% of PDAC cases, the expression of HHLA2 is strongly associated with an improved post-surgical prognosis, indicating functions of HHLA2 as a costimulatory ligand in pancreatic cancer, activating CD8+ T cell proliferation and improving patient prognosis (Yan et al., 2019).